Loading...
Market
What will be the outcome of the FDA review of Kezar Life Sciences' Zetomipzomib Lupus Nephritis trial by March 31, 2025?
2
Resolution / Starting Odds
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Official announcements from the FDA or Kezar Life Sciences
Story
Kezar Life Sciences Voluntarily Halts Enrollment in Zetomipzomib Lupus Nephritis Trial
Sep 30, 2024, 12:24 PM
Kezar Life Sciences has announced the voluntary cessation of enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision follows a recent review of emerging safety data by the Independent Data Monitoring Committee (IDMC), which included an assessment of four Grade 5 (fatal) serious adverse events (SAEs). The company is notifying the FDA and EMA but has not yet received a clinical hold letter.
View original story
Similar markets
Approved without conditions • 25%
Approved with conditions • 25%
Approval delayed • 25%
Not approved • 25%
Yes • 50%
No • 50%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Primary endpoint met with significant improvement • 25%
Primary endpoint met with moderate improvement • 25%
Primary endpoint not met • 25%
Trial inconclusive or delayed • 25%
Breakthrough Therapy • 25%
Fast Track • 25%
Orphan Drug • 25%
No designation • 25%
Yes • 50%
No • 50%
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
Approved • 33%
Rejected • 33%
Request for more data • 34%